SCHEMBL26618136

SCHEMBL26618136

O=C(CBr)c1cccc(NC2CC(F)(F)C2)n1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.39
IDH1 O75874 6/20 0.36
IDH2 P48735 3/20 0.36
TRPA1 O75762 1/20 0.34
KIF18A Q8NI77 1/20 0.34
KDM1A O60341 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
PRMT5 O14744 1/20 0.33
GRM5 P41594 2/20 0.33
HPGD P15428 1/20 0.33
PTPN1 P18031 2/20 0.32
ROCK2 O75116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26618081 0.75 IDH1 (0.42) IDH1IDH2
SCHEMBL17115670 0.75 IDH1 (0.37) GRM4IDH1IDH2TRPA1KIF18A
SCHEMBL26618090 0.74 NOS2 (0.36) GRM4IDH1IDH2TRPA1KIF18A
SCHEMBL28832571 0.73 IDH1 (0.43) IDH1IDH2
SCHEMBL15710124 0.73 IDH1 (0.36) GRM4IDH1IDH2TRPA1KIF18A
SCHEMBL28712036 0.72 KDM4E (0.52) KDM4ELMNAPTPN1
SCHEMBL9297719 0.71 KDM4E (0.66) KDM4ELMNAGRM5HPGD
SCHEMBL20391199 0.69 P2RX7 (0.49) GRM4IDH1GRM5
SCHEMBL17700614 0.68 GRM4 (0.45) GRM4IDH1IDH2TRPA1MAPK1
SCHEMBL9297961 0.68 KDM4E (0.43) KDM4ELMNAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514790-A1 COMPOUNDS FOR INHIBITING KIF18A Volastra Therapeutics, Inc. (US) 2025-03-05 EP disclosed
CN-119451951-A Compounds for inhibition of KIF18A 沃拉斯查疗法公司 2025-02-14 CN disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-30 US disclosed
WO-2023212240-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
WO-2023212240-A1 COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382889-A1 COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C GRM4 3501/4885IDH1 1208/4885IDH2 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.